A company developing a portfolio of therapeutic cannabinoids for neurological conditions was seeking a stock exchange listing and asked Alacrita to develop documentation supporting its prospectus.
Specifically, we were asked to:
1. Write an independent Market Report on its two lead products.
2. Provide support in developing a Business Plan.
For the Market Report, Alacrita assessed the scientific rationale behind each of the lead products, the clinical data collected to date and the proposed clinical development plans. We used this information to create an independent report proposing feasible pricing in each indication and the available patient population, market share and market penetration.
Alacrita met with the company and its financial advisors to discuss both the contents of the report and the company strategy. Subsequently we provided further support in creating a professionally structured Business Plan.